Beaufort Securities restated their speculative buy rating on shares of Tissue Regenix Group PLC (LON:TRX) in a research report released on Thursday morning.

Separately, Jefferies Group upped their price target on shares of Tissue Regenix Group PLC from GBX 35 ($0.43) to GBX 40 ($0.50) and gave the company a buy rating in a research note on Monday, July 11th.

Shares of Tissue Regenix Group PLC (LON:TRX) traded down 4.2092% during mid-day trading on Thursday, reaching GBX 17.1226. 1,107,597 shares of the company’s stock traded hands. The firm has a 50 day moving average price of GBX 19.16 and a 200-day moving average price of GBX 19.36. The stock’s market cap is GBX 127.25 million. Tissue Regenix Group PLC has a 12 month low of GBX 12.70 and a 12 month high of GBX 22.50.

Tissue Regenix Group PLC Company Profile

Tissue Regenix Group plc is a medical technology company. The Company is engaged in the development of regenerative products to make replacement native tissue using biological (human and animal) tissues. It operates through Cardiac, Wound Care and Orthopaedics divisions. Its decellularisation (dCELL) technology removes deoxyribonucleic acid and other cellular material from tissue leaving an acellular scaffold, which is not rejected by the patient’s body.

Receive News & Stock Ratings for Tissue Regenix Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tissue Regenix Group PLC and related stocks with our FREE daily email newsletter.